Keytruda® (pembrolizumab) – New indication
June 13, 2025, - Merck announced the FDA approval of Keytruda (pembrolizumab), for the treatment of adult patients with resectable locally advanced head and neck squamous cell cancer (HNSCC) whose tumors express PD-L1 (Combined Positive Score [CPS] ≥ 1) as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy with or without cisplatin and then as a single agent.
Top